Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
FULC
#2892
Fulcrum Therapeutics, Inc. Common Stock
7.9
1
USD
+2.33%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+2.33%
Changement Mensuel
+1.80%
Evolution sur 6 mois
-9.60%
Changement Annuel
+171.82%
Clôture Précédente
7.7
3
Open
7.9
0
Bid
Ask
Low
7.9
0
High
7.9
1
Volume
243
Marchés
Actions des Marchés US
Soins de Santé
FULC
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
32.67 M
40.64 M
61.76 M
61.94 M
53.98 M
66.6 M
—
Valuation ratios
Enterprise value
325.54 M
683.46 M
452.8 M
420.99 M
195.49 M
555.72 M
1.45 B
Price to earnings ratio
—
—
-3.24
-4.53
-29.38
-9.58
-14.02
Price to sales ratio
—
—
0.06
0.16
0
—
—
Price to cash flow ratio
—
—
-0
-0
-0.13
-0.01
-0.08
Price to book ratio
—
—
0
0
0
0
0.01
Enterprise value to EBITDA ratio
-4.7
-8.78
-4.12
-3.68
-7.92
-6.44
-23.07
Profitability ratios
Return on assets %
-0.55
-0.34
-0.48
-0.38
-0.04
-0.2
-0.3
Return on equity %
-0.74
-0.38
-0.55
-0.41
-0.04
-0.21
-0.31
Return on invested capital %
-694.39
-255.15
-242.06
-217.3
-41.52
-188.47
—
Gross margin %
100
100
100
100
100
—
—
Operating margin %
-811.64
-422.97
-1 774.85
-3 945.24
-27.37
—
—
EBITDA margin %
-785.45
-406.34
-1 734.39
-4 081.39
-30.87
—
—
Net margin %
-802.66
-421.89
-1 732.43
-3 470.05
-12.16
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
4.47
11.77
12.41
17.71
22.63
27.4
98.22
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.11
0.03
0.01
0.31
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2 157.1
-1 483.69
-35.78
-948.07
-270.23
EBIT per share
—
—
-2 501.86
-1 804.99
-353.27
-1 338
-365.49
EBITDA per share
—
—
-2 444.82
-1 867.28
-398.43
-1 362.67
-364.83
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
780.11
416.95
939.15
3 117.88
3 133.39
Net current asset value per share
—
—
4 612.46
3 950.4
4 032.06
5 642.49
5 719.88
Tangible book value per share
—
—
4 421.82
3 836.13
3 920.92
5 508.64
5 518.9
Working capital per share
—
—
4 240.71
3 727.35
3 853.88
5 436.54
5 510.55
Book value per share
—
—
4 421.82
3 836.13
3 920.92
5 508.64
5 584.08
Nouvelles
Leerink réitère sa note sur Fulcrum Therapeutics face à la flexibilité de la FDA
L’action Fulcrum jugée sous-évaluée alors que Stifel évoque la flexibilité de la FDA
Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher
Fulcrum Therapeutics à la conférence Leerink : focus stratégique
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell
L’action Fulcrum Therapeutics pourrait subir des pressions suite au retrait d’Ipsen, selon Stifel
Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC)
Le titre Fulcrum Therapeutics chute après l’échec d’un essai clinique
Fulcrum Therapeutics stock falls as sickle cell trial misses target
Leerink réitère sa recommandation sur Fulcrum Therapeutics après les données sur la drépanocytose
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data